CGAS and cancer: Cisplatin, one of the cancer chemotherapeutic drugs, could activate the cGAS-STINGTBK1 to initiate IRF3-dependent innate immune response, resulting in the generation of IFNs and a NF-κB-dependent inflammatory response, and consequently which leads to synthesis of pro-inflammatory factors, such as TNFα.